| Literature DB >> 33188394 |
Sarah Kim-Hellmuth1, Matthias Hermann2, Julia Eilenberger1, Julia Ley-Zaporozhan3, Marcus Fischer2, Fabian Hauck1, Christoph Klein1,4, Nikolaus Haas2, Matthias Kappler1, Johannes Huebner1,4, André Jakob2, Ulrich von Both1,4.
Abstract
Down syndrome (DS) predisposes to severe immunologic reaction secondary to infectious triggers. Here, we report a pediatric DS patient with coronavirus disease 2019 (COVID-19) who developed a hyperinflammatory syndrome, severe acute respiratory distress syndrome, and secondary hemophagocytic lymphohistiocytosis requiring pediatric intensive care unit admission and treatment with steroids, intravenous immunoglobulin, and remdesivir. Investigations into genetic susceptibilities for COVID-19 and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-associated complications warrant systematic clinical and scientific studies. We report a pediatric Down syndrome patient with coronavirus disease 2019 (COVID-19) who developed secondary hemophagocytic lymphohistiocytosis requiring treatment with steroids, intravenous immunoglobulin, and remdesivir. Investigations into genetic susceptibilities for COVID-19-associated complications warrant systematic clinical and scientific studies.Entities:
Keywords: Down syndrome; hyperinflammation; pediatrics; remdesivir; sHLH
Year: 2021 PMID: 33188394 PMCID: PMC7717321 DOI: 10.1093/jpids/piaa148
Source DB: PubMed Journal: J Pediatric Infect Dis Soc ISSN: 2048-7193 Impact factor: 3.164